July 03, 2012Besides delivering high-quality products and services in the field of transporters, SOLVO Biotechnology is also committed to educating the professional community on transporter-related topics. The company's educational efforts have received warm welcome in the market. The latest example of this successful initiative has been a webinar presented on June 25, 2012 by Jashvant Unadkat, Ph.D., Professor of Pharmaceutics in the School of Pharmacy at the University of Washington, Seattle. The webinar, entitled Principles of Transporter Drug Interactions with Special Focus on Hepatic and BBB Transporters, was attended by nearly 200 professionals from all over the world. Transporters are involved in clinically significant drug-drug interactions (DDI). Such interactions can occur at multiple sites, including in organs important in drug absorption (e.g. intestine), elimination (e.g. liver and kidneys) and distribution (e.g. brain). Notably, some of these interactions can be “hidden”, occurring in a tissue with no discernible trace in the systemic circulation. In addition, for drugs that are both transported and metabolized, DDIs will be most prominent when they occur at the “rate-limiting step” in the clearance of the drug. Thus, identifying this step is important for predicting such DDI. To illustrate such interactions, Professor Unadkat focused on clinically relevant DDI at these sites, involving P-glycoprotein, OATPs, and other transporters. The presentation also discussed IVIVC of these interactions, and covered P-glycoprotein based DDI at the human blood-brain barrier measured by PET imaging. Learn further details of the webinar and Professor Jashvant Unadkat, watch the recording, download the slides here (requires free registration)!
Next entry: EMA publishes new Guideline